The FDA announced the availability of a draft guidance designed to assist the research community in interpreting requirements for submitting reports of unanticipated problems such as certain adverse events reports to Institutional Review Board (IRB).
The FDA announced the availability of a draft guidance designed to assist the research community in interpreting requirements for submitting reports of unanticipated problems such as certain adverse events reports to Institutional Review Board (IRB). The agency developed the draft guidance in response to concerns raised by the IRB community that large volumes of individual adverse event reports are increasingly inhibiting rather than enhancing IRBs? ability to adequately protect human subjects. The guidance provides recommendations to IRB sponsors and investigators on how to improve the usefulness of the adverse event information submitted to IRBs.
To see more Hot off the Press news articles, click here.
To go to the Drug Topics homepage, click here.
Pharmacists Play Unique Role in Advancing Health Equity for Patients With Chronic Disease
December 7th 2023A new study, outlined in a poster at ASHP Midyear 2023, identified 3 key themes associated with the ways in which pharmacists are positioned to advance health equity for patients with chronic diseases.